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Reply. We thank Drs Siah and Gwee for their
interest in our study, in which we reported an 
exploratory factor analysis of Rome IV symp-toms (Clevers et al1), which we refer to as the Rome IV 
exploratory model (R4EM) similar to Siah and Gwee. The 
Rome IV consensus uses an anatomic basis to subdivide
Table 1. Comparison of the Rome IV, AFGID, and R4EM Symptom Factors in Adults
Rome IV AFGID R4EM
Esophageal A1. Chest pain Chest pain and heartburn Chest pain and heartburn
A2. Functional heartburn
A3. Reflux hypersensitivity
A4. Globus Globus, dysphagia, odynophagia Globus, dysphagia, odynophagia
A5. Functional dysphagia
Gastroduodenal B1a. Postprandial Distress Syndrome (PDS) Upper abdominal symptoms
B1b. Epigastric Pain Syndrome (EPS)
B2a. Gastric belching
B2b. Esophageal belching








Pain D. Abdominal pain Abdominal pain
Outside Rome IV Meal-related bowel symptoms
Upper abdominal pain with constipation
Bloating, fullness, belching, flatulence
IBS, irritable bowel syndrome.functional gastrointestinal disorders (Table 1). In their
Letter to the Editor,2 Drs Siah and Gwee made 2 points.
First, they stated that R4EM did not quite mirror the
Rome IV diagnostic classification. Although we agree that
not all disorders defined in Rome IV were captured by
the exploratory factor analysis in R4EM, our confirma-
tory factor analysis showed empirically that agreement
with the Rome IV diagnostic classification in R4EM was
quite good (Table 1). R4EM thus largely reinforces the
Rome IV criteria and their use in research and clinical
care.
Second, Siah and Gwee highlight similarities between
R4EM and an Asian Rome III factor analysis by Siah et al
(Asian Functional Gastrointestinal Disorder [AFGID]
Symptom Clusters).3 We agree that both studies share
important similarities. For instance, both identified a
globus/dysphagia factor, a heartburn/chest pain factor,
and a nausea/vomiting factor (Table 1). The main find-
ings of AFGID were symptom factors characterized by
upper abdominal symptoms, associated with bowel
function. This type of overlapping conditions is not
considered in the Rome consensus and its predominantly
anatomic subdivision. The question is how specific this is
to the questionnaire used in AFGID and symptom ex-
pressions or perceptions in Asia, or whether this is an
inherent flaw in the Rome approach.4
Drs Siah and Gwee argue that overlap between upper-
and lower-tract symptoms also is present in R4EM
because loose stools after a meal was part of the diarrhea
factor in our analysis. However, this refers to the timing
of bowel symptoms in relation to an upper gastrointes-
tinal event (meal intake), rather than location of bowel-
associated symptoms in the upper abdomen. Theoccurrence of bowel symptoms in relation to a meal is
not novel and is well established in the literature.5,6
The current R4EM analyses found that the lower GI
symptoms were not significantly associated with upper
GI symptom locations, and vice versa, as shown in
Table 1. Hence, taken together, the R4EM adheres most
closely to the Rome IV consensus and differs more
significantly from the AFGID findings.
However, although factor analysis is a useful tool to
validate the Rome questionnaire, this type of analysis is
also sensitive to wording and content of questions and
various statistical choices, and should be interpreted
critically. When comparing the findings of AFGID and
R4EM, one needs to take into account that AFGID was
conducted in patients presenting to gastroenterology
clinics, which may already account for some of the dif-
ferences. In addition, R4EM used the Rome IV question-
naire, and, hence, confirming categories close to the Rome
IV criteria should not come as a surprise. The AFGID
questionnaire was based on the Rome III consensus, but
adapted and expanded, taking into account Asian lan-
guages, culture, and symptom expressions.3 Because these
adaptations were not performed in R4EM, the current
analysis cannot deny the relevance of these adaptations.
We are highly appreciative of the contribution of Drs
Siah and Gwee, and colleagues in their AFGID report and
in the current letter.2,3 It is also our opinion that the
Rome questionnaire, enriched with the questions and
concepts as used in AFGID, should be used in a large
population of patients (and perhaps the general
population) in the West, to determine whether or not
the overlapping factors also are found in this part of
the world, which would be a major step ahead in
EGBERT CLEVERS, PhD




Department of Internal Medicine and
Clinical Nutrition, Institute of Medicine
Sahlgrenska Academy, University of Gothenburg
Gothenburg, Sweden
WILLIAM E. WHITEHEAD, PhD
OLAFUR S. PALSSON, PhD
Center for Functional Gastrointestinal and
Motility Disorders
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
AMI D. SPERBER, MD
Faculty of Health Sciences,
Ben-Gurion University of the Negev
Beer-Sheva, Israel
HANS TÖRNBLOM, MD
Department of Internal Medicine and
Clinical Nutrition, Institute of Medicine
Sahlgrenska Academy, University of Gothenburg
Gothenburg, Sweden
LUKAS VAN OUDENHOVE, MD
JAN TACK, MD





Department of Internal Medicine and
Clinical Nutrition, Institute of Medicine
Sahlgrenska Academy, University of Gothenburg
Gothenburg, Sweden
Center for Functional Gastrointestinal and
Motility Disorders
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
developing a universal symptom analysis and 
categorization system. Meanwhile, in the West, the 
Rome IV subdivision seems to have a solid basis for 
current use in clinical practice and research, while we 
continue research to increase our knowledge and 
insights. The Rome Foundation will soon publish the 
results of a 32-country global epidemiologic study 
including 8 countries from Asia. Although that study’s 
questionnaire was not enriched with the questions and 
concepts used in AFGID as discussed earlier, it will 
provide an excellent opportunity to look further into 
potential differences between East and West based on 
the Rome IV diagnostic questionnaire and many 
potentially associated factors that might explain some 
of the differences, if found.References
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